reactiv hepat viru replic patient cytotox therapi report prospect studi chines patient induct cytotox therapi malign lymphoma incid morbid mortal factor reactiv hepat viru replic cytotox therapi hepat surfac antigen-posit hepat surfac antigen-neg patient hepat cytotox therapi hepat exacerb reactiv chronic hepat hepat surfac antigen-posit patient hepat surfac antigen-neg patient sudden increas reactiv hepat viru replic rise hepat nonfat hepat failur death patient posit hepat surfac antigen posit hepat antibodi none seroneg hepat surfac antigen-posit patient male sex factor risk reactiv hepat viru replic hepat surfac antigen-posit patient malign cytotox therapi 